Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The daily Top 10 COVID papers

Leukemia

Free Subscription 18.01.2021 1 Acta Haematol 1 Am J Clin Pathol 6 Ann Hematol 2 BMC Cancer 12 Br J Haematol 2 Cancer 2 Cancer Res 1 Eur J Haematol 1 Exp Cell Res 1 Exp Hematol 1 Genes Chromosomes Cancer 1 Int J Hematol 4 J Clin Oncol 1 J Pediatr Hematol Oncol 3 Leuk Lymphoma 4 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. MAITI A, Franquiz MJ, Ravandi F, Cortes JE, et al
   Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
   Acta Haematol. 2020;143:567-573.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. HORNA P, Olteanu H, Jevremovic D, Otteson GE, et al
   Single-Antibody Evaluation of T-Cell Receptor beta Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia.
   Am J Clin Pathol. 2021 Jan 13. pii: 6092418. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. AMIT O, On YB, Perez G, Shargian-Alon L, et al
   Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
   Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-021-04398.
   PubMed         Abstract available
   
   
4. MARTIN-MORO F, Garcia-Cosio M, Marquet-Palomanes J, Lopez-Gutierrez M, et al
   Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
   Ann Hematol. 2021 Jan 9. pii: 10.1007/s00277-021-04393.
   PubMed        
   
   
5. KERUAKOUS AR, Balakrishna P, Schmidt SA, Autry MT, et al
   Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.
   Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04408.
   PubMed        
   
   
6. SCHLAWECK S, Brossart P, Heine A
   Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.
   Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04403.
   PubMed        
   
   
7. LIAO PW, Wang RC, Chen TC, Teng CJ, et al
   Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
   Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-020-04372.
   PubMed        
   
   
8. VOIGT M, Sinn K, Malouhi A, Gecks T, et al
   HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient.
   Ann Hematol. 2021 Jan 14. pii: 10.1007/s00277-021-04409.
   PubMed        
   
   

   
   BMC Cancer

9. LI XY, Li JQ, Luo XQ, Wu XD, et al
   Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
   BMC Cancer. 2021;21:59.
   PubMed         Abstract available
   
   
10. MOHAMMADZADEH Z, Omidkhoda A, Chahardouli B, Hoseinzadeh G, et al
    The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
    BMC Cancer. 2021;21:46.
    PubMed         Abstract available
    
    

    
    Br J Haematol

11. JIANG Y, Li Y, Cheng J, Ma J, et al
    Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
    Br J Haematol. 2020;189:694-706.
    PubMed         Abstract available
    
    
12. CHEN X, Chen H
    BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:591.
    PubMed        
    
    
13. CICIARELLO M, Curti A
    Good news for acute myeloid leukaemia patients from the stroll niche?
    Br J Haematol. 2020;189:597-599.
    PubMed        
    
    
14. MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
    Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    Br J Haematol. 2020;189:689-693.
    PubMed         Abstract available
    
    
15. UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
    Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Br J Haematol. 2020;189:745-750.
    PubMed         Abstract available
    
    
16. ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
    Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
    Br J Haematol. 2020;189:672-683.
    PubMed         Abstract available
    
    
17. PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
    Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
    Br J Haematol. 2020;189:718-730.
    PubMed         Abstract available
    
    
18. ROBINSON SE, Harrison CN
    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Br J Haematol. 2020;189:625-634.
    PubMed         Abstract available
    
    
19. GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
    Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e150-e154.
    PubMed        
    
    
20. INABA H, Cao X, Chang JY, Karol SE, et al
    Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e177-e181.
    PubMed        
    
    
21. ADELAIDE J, Cervera N, Guille A, Murati A, et al
    Gains of EPOR and ERG genes in adult erythroleukaemia.
    Br J Haematol. 2020;189:e174-e177.
    PubMed        
    
    
22. RAYMOND LM, Funk T, Braziel RM, Fan G, et al
    Mast cell sarcoma with concurrent mast cell leukaemia.
    Br J Haematol. 2020;189:e160-e164.
    PubMed        
    
    

    
    Cancer

23. ORAN B, Garcia-Manero G, Saliba RM, Alfayez M, et al
    Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
    Cancer. 2020;126:2193-2205.
    PubMed         Abstract available
    
    
24. ABOU DALLE I, Kantarjian HM, Ravandi F, Daver N, et al
    Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33409.
    PubMed         Abstract available
    
    

    
    Cancer Res

25. STIEHL T, Wang W, Lutz C, Marciniak-Czochra A, et al
    Mathematical Modeling Provides Evidence for Niche Competition in Human AML and Serves as a Tool to Improve Risk Stratification.
    Cancer Res. 2020;80:3983-3992.
    PubMed         Abstract available
    
    
26. TOHUMEKEN S, Baur R, Bottcher M, Stoll A, et al
    Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling.
    Cancer Res. 2020;80:3663-3676.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

27. GEISSLER K, Jager E, Barna A, Graf T, et al
    Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
    Eur J Haematol. 2021 Jan 12. doi: 10.1111/ejh.13577.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

28. WANG C, Li L, Li M, Shen X, et al
    Corrigendum to "Inactivated STAT5 pathway underlies a novel inhibitory role of EBF1 in chronic lymphocytic leukemia" [Exp. Cell Res. 398(1) 112371].
    Exp Cell Res. 2021 Jan 8:112469. doi: 10.1016/j.yexcr.2020.112469.
    PubMed        
    
    

    
    Exp Hematol

29. FITCH B, Roy R, Geng H, Montecino-Rodriguez E, et al
    Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature.
    Exp Hematol. 2020;90:65-71.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

30. ORSMARK-PIETRAS C, Landberg N, Lorenz F, Uggla B, et al
    Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
    Genes Chromosomes Cancer. 2021 Jan 12. doi: 10.1002/gcc.22936.
    PubMed         Abstract available
    
    

    
    Int J Hematol

31. SAKAMOTO H, Itonaga H, Sawayama Y, Kojima A, et al
    Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy.
    Int J Hematol. 2021 Jan 10. pii: 10.1007/s12185-020-03075.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

32. KHALDOYANIDI S, Nagorsen D, Stein A, Ossenkoppele G, et al
    Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
    J Clin Oncol. 2021 Jan 12:JCO2000475. doi: 10.1200/JCO.20.00475.
    PubMed        
    
    
33. O'NEILL AT, Chakraverty R
    Graft Versus Leukemia: Current Status and Future Perspectives.
    J Clin Oncol. 2021 Jan 12:JCO2001801. doi: 10.1200/JCO.20.01801.
    PubMed         Abstract available
    
    
34. LUSSANA F, Gritti G, Rambaldi A
    Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    J Clin Oncol. 2021 Jan 12:JCO2001564. doi: 10.1200/JCO.20.01564.
    PubMed        
    
    
35. AGRAWAL AK, Michlitsch J, Golden C, Hastings CA, et al
    Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
    J Clin Oncol. 2021 Jan 14:JCO2002973. doi: 10.1200/JCO.20.02973.
    PubMed        
    
    

    
    J Pediatr Hematol Oncol

36. OBEROI S, Dawson A, Marko D, Almiski M, et al
    Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent.
    J Pediatr Hematol Oncol. 2021 Jan 11. pii: 00043426-900000000-97026.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

37. GHIA P, Dlugosz-Danecka M, Scarfo L, Jurczak W, et al
    Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jan 11:1-18. doi: 10.1080/10428194.2020.1864352.
    PubMed         Abstract available
    
    
38. LI SY, Lu Y, Liu HC, Gang EJ, et al
    Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2021 Jan 13:1-6. doi: 10.1080/10428194.2020.1856832.
    PubMed        
    
    
39. GARCIA-HORTON A, Maze D, McNamara CJ, Sibai H, et al
    Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
    Leuk Lymphoma. 2021 Jan 15:1-6. doi: 10.1080/10428194.2020.1869961.
    PubMed        
    
    

    
    Leukemia

40. O'NIONS J, Muir L, Zheng J, Rees-Spear C, et al
    SARS-CoV-2 antibody responses in patients with acute leukaemia.
    Leukemia. 2021;35:289-292.
    PubMed        
    
    
41. SWOBODA DM, Ali NA, Chan O, Padron E, et al
    PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
    Leukemia. 2021;35:286-288.
    PubMed        
    
    
42. NOFRINI V, Matteucci C, Pellanera F, Gorello P, et al
    Activating somatic and germline TERT promoter variants in myeloid malignancies.
    Leukemia. 2021;35:274-278.
    PubMed        
    
    
43. NAGATE Y, Ezoe S, Fujita J, Okuzaki D, et al
    Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
    Leukemia. 2021;35:107-118.
    PubMed         Abstract available
    
    

    
    PLoS One

44. MASHIMA K, Oh I, Fujiwara K, Izawa J, et al
    Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models.
    PLoS One. 2021;16:e0245232.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: